Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Update

Key Points

• Spero Therapeutics experienced a significant decline in short interest, with a drop of 45.6% in August, resulting in a total of 504,000 shares shorted by the end of the month.
• Wall Street analysts rated Spero Therapeutics with a consensus of "Moderate Buy" and a target price of $5.00, with recent ratings varying between "Buy" and "Hold."
• The company reported earnings of ($0.03) EPS for the recent quarter, exceeding expectations and generating revenues of $14.19 million.

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) saw a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 504,000 shares, a drop of 45.6% from the August 15th total of 927,200 shares. Based on an average daily trading volume, of 942,100 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.9% of the shares of the company are short sold. Approximately 0.9% of the shares of the company are short sold. Based on an average daily trading volume, of 942,100 shares, the days-to-cover ratio is presently 0.5 days.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Spero Therapeutics to a "hold" rating in a research report on Saturday, June 21st. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Spero Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $5.00.

Institutional Investors Weigh In On Spero Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC purchased a new stake in Spero Therapeutics in the 2nd quarter worth $455,000. Invesco Ltd. purchased a new stake in Spero Therapeutics in the 2nd quarter worth $43,000. Quadrature Capital Ltd purchased a new stake in shares of Spero Therapeutics during the second quarter worth $90,000. XTX Topco Ltd purchased a new stake in shares of Spero Therapeutics during the second quarter worth $100,000. Finally, Axxcess Wealth Management LLC purchased a new stake in shares of Spero Therapeutics during the second quarter worth $94,000. Hedge funds and other institutional investors own 25.60% of the company's stock.

Spero Therapeutics Price Performance

SPRO opened at $1.90 on Friday. The firm has a fifty day moving average price of $2.22 and a 200 day moving average price of $1.63. Spero Therapeutics has a 1 year low of $0.51 and a 1 year high of $3.22. The stock has a market cap of $106.92 million, a P/E ratio of -1.94 and a beta of 1.46.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.35. Spero Therapeutics had a negative net margin of 110.35% and a negative return on equity of 120.27%. The firm had revenue of $14.19 million during the quarter, compared to analysts' expectations of $11.00 million. Equities analysts expect that Spero Therapeutics will post -1.2 EPS for the current year.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.